Inhibikase Therapeutics, Inc. (IKT) › Capital ExpendituresInhibikase Therapeutics, Inc. (IKT) — Capital ExpendituresAnnual figures by period end, from SEC filings.2021-12-31: $02022-12-31: $243.3K2023-12-31: $14.2K2024-12-31: $02025-12-31: $13.4K$13.4K2021-12-31Capital Expenditures (USD)2025-12-31Period endedCapital ExpendituresChange YoYSource filing2025-12-31$13.4K—2026-03-26From 2025-01-012024-12-31$0-100.0%2026-03-26From 2024-01-012023-12-31$14.2K-94.1%2025-03-27From 2023-01-012022-12-31$243.3K—2024-03-27From 2022-01-012021-12-31$0—2023-03-31From 2021-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)